In end-stage disease, the person

Chronic obstructive pulmonary disease and emphysema is a chronic progressive disorder characterized by

airflow limitation. They are essentially progressive

conditions that worsen with time, especially if the person continues to smoke. Pulmonary rehabilitation (for optimal fitness) can reduce symptoms and improve

function. Controlled oxygen therapy for more than 15 hours

day has been shown to increase survival significantly. Quitting smoking is the most effective measures for reducing risk >> << for future development. Quitting smoking can slow the decline >> << lung function to normal levels decline in a relatively short time. This will not affect the prediction of medium and severe illness, because

injured, but can improve prognosis in mild disease. Weather in moderate to severe COPD therefore likely to be for life >> << followed by care and mobility needs that will not improve as the disease is progressive

, and the person can gradually deteriorate. At first the only symptom for many years may be >> << smokers cough. This symptom progresses cough with phlegm, wheeze and shortness of breath. Breast infections occur more and more regularly in cold causes >> << sputum production. These infections increase the intensity and duration, while cough >> << pervasive. As the disease progresses, the person feels increasing >> << dyspnea on exertion. In later stages of the disease, shortness of breath becomes difficult and is in the rest

and usually affects all aspects of daily life. In end-stage disease, the person

to bed or chair bound framework and will probably be on oxygen for several hours

day. This is a chronic, slowly progressive disease with little >> << shift on time. Broncholytic therapy can help the degree of airway obstruction in some

degree, since most patients have some degree of asthmatic reactions such as

to bronchodilators. 20-30% of patients somewhat improved if this course >> << steroids and inhaled corticosteroids may be indicated. Long-term oral corticosteroid treatment

usually be avoided. The disease is seen as progressive, continuous

steady decline in lung function. In all cases - indefinite award the best predictor of survival in FEV1 after broncholytic use. Emphysema develops gradually over several years. People with emphysema have great difficulty in breathing out (exhalation). Symptoms such as shortness of breath (sometimes associated with wheezing)

appear at first load, and with the progression of the disease with low voltage >> << and ultimately alone. The man eventually be able >> << do basic work in normal mode. In later stages of the disease, shortness of breath becomes difficult and is in the rest >> << and >> << usually affects all aspects of daily life. In end-stage disease, one bed or chair-related and probably related

to be on oxygen for several hours a day. This is a chronic, slowly progressive disease with little change for

period of time. Broncholytic therapy can help those who tend to lasix drug interactions narrow the airways. In some patients a little better, if this course of steroids and inhaled corticosteroids >> << can be specified. Long-term oral corticosteroid treatment

should be avoided. No treatment has been shown to restore lost lung function. In all cases - indefinite award All information should be taken into account when considering

playing off effects and duration of disabling effects must

based on the specific circumstances of individual applicant. .